Management of schizophrenia: clinical experience with asenapine

Show simple item record

dc.contributor.author Cortese, Leonardo
dc.contributor.author Bressan, Rodrigo A. [UNIFESP]
dc.contributor.author Castle, David J.
dc.contributor.author Mosolov, Sergey N.
dc.date.accessioned 2016-01-24T14:31:33Z
dc.date.available 2016-01-24T14:31:33Z
dc.date.issued 2013-04-01
dc.identifier http://dx.doi.org/10.1177/1359786813482533
dc.identifier.citation Journal of Psychopharmacology. London: Sage Publications Ltd, v. 27, n. S4, p. 14-22, 2013.
dc.identifier.issn 0269-8811
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/36188
dc.description.abstract Schizophrenia is a chronic brain disorder comprising a range of clinical features, including positive and negative symptoms, cognitive dysfunction and mood symptoms (particularly depression and anxiety). the management of schizophrenia requires effective short- and long-term treatment with antipsychotic medication that is effective across these symptom domains, while being well tolerated over the long term. Asenapine is the first tetracyclic atypical antipsychotic to be licensed in the USA and several other countries outside Europe for the acute and maintenance treatment of schizophrenia in adults. It has a unique receptor-binding profile and a broad range of therapeutic effects. Since clinical trials are conducted under strict conditions in tightly defined patient populations, evidence of an agent's efficacy and tolerability under real-world' clinical practice conditions is also required. As in clinical trials, real-life case reports demonstrate that asenapine is effective in treating the positive symptoms of schizophrenia, both in the acute setting and for relapse prevention. It is also effective in treating negative symptoms and shows promise in the treatment of depressive symptoms associated with schizophrenia. Asenapine has a favourable tolerability profile, having a minimal impact on weight and metabolic parameters. As such, asenapine is valuable option for the treatment of schizophrenia in adults. en
dc.description.sponsorship H Lundbeck A/S through mXm Medical Communications
dc.format.extent 14-22
dc.language.iso eng
dc.publisher Sage Publications Ltd
dc.relation.ispartof Journal of Psychopharmacology
dc.rights Acesso restrito
dc.subject Asenapine en
dc.subject atypical antipsychotic en
dc.subject cognition en
dc.subject depressive symptoms en
dc.subject negative symptoms en
dc.subject positive symptoms en
dc.subject relapse prevention en
dc.subject schizophrenia en
dc.title Management of schizophrenia: clinical experience with asenapine en
dc.type Artigo
dc.rights.license http://www.uk.sagepub.com/aboutus/openaccess.htm
dc.contributor.institution Univ Western Ontario
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution St Vincents Hosp
dc.contributor.institution Univ Melbourne
dc.contributor.institution Moscow Res Inst Psychiat
dc.description.affiliation Univ Western Ontario, Fac Med, Windsor Reg Hosp, Windsor, ON, Canada
dc.description.affiliation Universidade Federal de São Paulo, Dept Psychiat, São Paulo, Brazil
dc.description.affiliation St Vincents Hosp, Melbourne, Vic, Australia
dc.description.affiliation Univ Melbourne, Melbourne, Vic, Australia
dc.description.affiliation Moscow Res Inst Psychiat, Moscow, Russia
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Dept Psychiat, São Paulo, Brazil
dc.identifier.doi 10.1177/1359786813482533
dc.description.source Web of Science
dc.identifier.wos WOS:000329543500002



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account